☆ 4.7 Article

Inhibition of CD39 unleashes macrophage antibody-dependent cellular phagocytosis against B-cell lymphoma

LEUKEMIA (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Hematology

Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission

Mazyar Shadman et al.

Summary: The relative efficacy of autologous hematopoietic cell transplant (auto-HCT) vs chimeric antigen receptor T-cell (CAR-T) therapy in patients with diffuse large B-cell lymphoma (DLBCL) who achieve a partial remission (PR) after salvage chemotherapy is not known. A study found that auto-HCT treatment was associated with a lower rate of relapse and superior overall survival compared to CAR-T treatment in DLBCL patients in PR after salvage therapy. These findings support auto-HCT as the standard of care for transplant-eligible patients with relapsed DLBCL in PR after salvage therapy.

BLOOD (2022)

添加到收藏夹

Article Hematology

A germinal center-associated microenvironmental signature reflects malignant phenotype and outcome of DLBCL

Kohta Miyawaki et al.

Summary: This study evaluated the impact of the microenvironment on clinical outcomes and molecular features in DLBCL. It found that the presence of normal GC-microenvironmental cells in lymphoma tissue is associated with a positive therapeutic response and established an independent prognostic model. Additionally, DLBCL tissues lacking GC-microenvironmental cells showed an increased incidence of genomic alterations and aberrant gene expression associated with poor prognosis.

BLOOD ADVANCES (2022)

添加到收藏夹

Article Hematology

Invariant NKT cells dictate antitumor immunity elicited by a bispecific antibody cotargeting CD3 and BCMA

Mika Casey et al.

Blood Advances (2022)

添加到收藏夹

Article Medicine, Research & Experimental

Glycoengineered anti-CD39 promotes anticancer responses by depleting suppressive cells and inhibiting angiogenesis in tumor models

Haohai Zhang et al.

Summary: Accumulation of immunosuppressive cells in the tumor microenvironment is a barrier to current immunotherapeutic approaches. Elevated expression of ectonucleotidase CD39 is a common feature of tumor-associated immune and vascular endothelial cells. The use of afucosylated anti-CD39 antibody can deplete immunosuppressive cells and block tumor angiogenesis through enhanced ADCC.

JOURNAL OF CLINICAL INVESTIGATION (2022)

添加到收藏夹

Article Oncology

Ectonucleotidase CD39 is highly expressed on ATLL cells and is responsible for their immunosuppressive function

Yasuhiro Nagate et al.

Summary: ATLL patients have a poor prognosis, with ATLL cells expressing CD39 and exhibiting immunosuppressive functions through the conversion of extracellular ATP into adenosine, allowing them to evade antitumor immunity.

LEUKEMIA (2021)

添加到收藏夹

Article Oncology

Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies

Stephen M. Ansell et al.

Summary: The study evaluated the safety and activity of TTI-621 in relapsed/refractory hematologic malignancies, indicating that TTI-621 demonstrated certain therapeutic effects and good tolerability overall in patients.

CLINICAL CANCER RESEARCH (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Imaging the mechanisms of anti-CD20 therapy in vivo uncovers spatiotemporal bottlenecks in antibody-dependent phagocytosis

Capucine L. Grandjean et al.

Summary: It was found that macrophages in the bone marrow are the main way to eliminate tumors, but they can only act on neighboring tumors and have a limited active time.

SCIENCE ADVANCES (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

ATP and cancer immunosurveillance

Oliver Kepp et al.

Summary: In the TME, intracellular ATP plays a critical role in bioenergetic metabolism, while extracellular ATP functions as a signal transducer, affecting biology dependent on receptor types, cell types, and regulatory circuitry activation status. Additionally, extracellular ATP is rapidly degraded, leading to the accumulation of metabolites with distinct biological effects.

EMBO JOURNAL (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Inter-cellular CRISPR screens reveal regulators of cancer cell phagocytosis

Roarke A. Kamber et al.

Summary: This study developed a platform for unbiased identification of factors that impede antibody-dependent cellular phagocytosis (ADCP) in cancer cells, revealing the important roles of the enzyme APMAP and the G-protein-coupled receptor GPR84 in this process. This helps to expand our knowledge of the mechanisms governing cancer resistance to macrophage phagocytosis.

NATURE (2021)

添加到收藏夹

Article Cell Biology

The P2X7 Receptor in Tumor Immunity

Fabio Grassi et al.

Summary: eATP, as a danger-associated molecular pattern, plays a role in immune response by stimulating P2 receptors. However, its impact in the tumor microenvironment is complex and not well-established.

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)

添加到收藏夹

Article Hematology

The microenvironment of DLBCL is characterized by noncanonical macrophages recruited by tumor-derived CCL5

Benoit Manfroi et al.

Summary: Tumor invasion induces inflammatory response, impacting tumorigenesis. DLBCL tumor cells express CCL5, recruiting blood monocytes. TAMs in DLBCL have a noncanonical gene signature, potentially explaining the lack of impact on DLBCL development.

BLOOD ADVANCES (2021)

添加到收藏夹

Review Immunology

The Cancer-Immunity Cycle in Multiple Myeloma

Mika Casey et al.

Summary: Multiple myeloma is a plasma cell malignancy that mainly affects the elderly population, and despite advancements in therapy, the need for new treatments remains pressing. Immune therapy is recognized as a key modality for improved clinical outcomes in myeloma patients, but understanding the immune system in these patients is still a challenge.

IMMUNOTARGETS AND THERAPY (2021)

添加到收藏夹

Review Oncology

Tumor-associated macrophages: potential therapeutic strategies and future prospects in cancer

Chunxiao Li et al.

Summary: Macrophages play a crucial role in the tumor microenvironment, where they can be polarized into tumor-associated macrophages (TAMs). The abundance of TAMs in tumors is closely linked with poor prognosis, leading to investigations into therapeutic strategies targeting TAMs. These strategies include inhibiting macrophage recruitment to tumors, repolarizing TAMs towards an anti-tumor phenotype, and inducing macrophage-mediated destruction of cancer cells. As tumor immunotherapy gains more importance, new anti-tumor strategies focusing on TAMs are being discussed.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

添加到收藏夹

Review Immunology

Myeloid immunosuppression and immune checkpoints in the tumor microenvironment

Kyohei Nakamura et al.

CELLULAR & MOLECULAR IMMUNOLOGY (2020)

添加到收藏夹

Review Oncology

On the mechanism of anti-CD39 immune checkpoint therapy

David Allard et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

添加到收藏夹

Article Oncology

Combination of CD47 and signal-regulatory protein-α constituting the don't eat me signal is a prognostic factor in diffuse large B-cell lymphoma

Ryo Kazama et al.

CANCER SCIENCE (2020)

添加到收藏夹

Article Oncology

Targeting an adenosine-mediated don't eat me signal augments anti-lymphoma immunity by anti-CD20 monoclonal antibody

Kyohei Nakamura et al.

LEUKEMIA (2020)

添加到收藏夹

Article Oncology

Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade

Rui Yang et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

添加到收藏夹

Review Hematology

Cancer immunoediting and immune dysregulation in multiple myeloma

Kyohei Nakamura et al.

BLOOD (2020)

添加到收藏夹

Review Oncology

The adenosine pathway in immuno-oncology

Bertrand Allard et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Hematology

Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma

Laetitia Vercellino et al.

BLOOD ADVANCES (2020)

添加到收藏夹

Article Medicine, Research & Experimental

Fully human anti-CD39 antibody potently inhibits ATPase activity in cancer cells via uncompetitive allosteric mechanism

Bradley N. Spatola et al.

MABS (2020)

添加到收藏夹

Article Cell Biology

Intercellular Calcium Signaling Induced by ATP Potentiates Macrophage Phagocytosis

Sara Zumerle et al.

CELL REPORTS (2019)

添加到收藏夹

Article Cell Biology

Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies

Ivan Perrot et al.

CELL REPORTS (2019)

添加到收藏夹

Article Hematology

EBV microRNA-BHRF1-2-5p targets the 3′UTR of immune checkpoint ligands PD-L1 and PD-L2

Alexandre S. Cristino et al.

BLOOD (2019)

添加到收藏夹

Review Oncology

Phagocytosis checkpoints as new targets for cancer immunotherapy

Mingye Feng et al.

NATURE REVIEWS CANCER (2019)

添加到收藏夹

Article Medicine, General & Internal

CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma

Ranjana Advani et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Article Immunology

Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy

Amira A. Barkal et al.

NATURE IMMUNOLOGY (2018)

添加到收藏夹

Article Multidisciplinary Sciences

Endotoxin-induced autocrine ATP signaling inhibits neutrophil chemotaxis through enhancing myosin light chain phosphorylation

Xu Wang et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)

添加到收藏夹

Review Oncology

TAMeless traitors: macrophages in cancer progression and metastasis

Shweta Aras et al.

BRITISH JOURNAL OF CANCER (2017)

添加到收藏夹

Article Hematology

Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study

Colm Keane et al.

LANCET HAEMATOLOGY (2015)

添加到收藏夹

Article Hematology

Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial

Sari Riihijarvi et al.

HAEMATOLOGICA (2015)

添加到收藏夹

Article Hematology

Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue

David W. Scott et al.

BLOOD (2014)

添加到收藏夹

Article Hematology

TLR stimulation initiates a CD39-based autoregulatory mechanism that limits macrophage inflammatory responses

Heather B. Cohen et al.

BLOOD (2013)

添加到收藏夹

Article Hematology

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

Bertrand Coiffier et al.

BLOOD (2010)

添加到收藏夹

Article Biochemistry & Molecular Biology

Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma

Mark P. Chao et al.

CELL (2010)

添加到收藏夹

Article Hematology

Rituximab: Mechanism of Action

George J. Weiner

SEMINARS IN HEMATOLOGY (2010)

添加到收藏夹

Article Hematology

Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcγRI, FcγRIII, and FcγRIV

Veronique Minard-Colin et al.

BLOOD (2008)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.